The association between worry, rumination, and metacognitive beliefs in female adolescents with Anorexia Nervosa
Editorial: Treatment resistant depression: epidemiology, clinic, burden and treatment, volume II
Governing the social production of care: the hidden foundation of health systems
Nature Medicine, Published online: 22 July 2026; doi:10.1038/s41591-026-04535-y
Health systems rely on unpaid care that is poorly measured and governed. We argue that unpaid care, and the wider social production system behind it, is a productive input whose breakdown drives avoidable admissions, delayed discharge, and labor-force exit. We propose a national accounting framework, a diagnostic lens, and five policy priorities.
FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial
Nature Medicine, Published online: 22 July 2026; doi:10.1038/s41591-026-04522-3
In a phase 1 trial, the maximum tolerated dose for an FcRH5-containing bispecific T cell engager was not reached, and there was an encouraging response rate in patients with relapsed or refractory multiple myeloma.
Cerebral venous blood flow regulates intracerebral pressure and brain clearance via meningeal lymphatic vessels
Nature Neuroscience, Published online: 22 July 2026; doi:10.1038/s41593-026-02358-1
The authors show that cerebral venous blood flow and meningeal lymphatics co-regulate intracranial pressure and brain clearance in mice and humans. This finding supports idiopathic intracranial hypertension as a cerebral venous disorder.
Why NHS EPR adoption has a design problem, not just a training problem
Engitix Licenses Lonza’s Technology to Advance ADC Therapies
Lonza and Engitix signed a licensing agreement to advance the development of antibody-drug conjugates (ADCs) as therapies for patients with chronic diseases.
Engitix will access Lonza’s ADC technology platform through a single-target license, including the use of SYNtecan E
linker-payload and complementary GlycoConnect® and HydraSpace®. These technologies are intended to support Engitix’s goal to develop and commercialize therapies.
Lonza, through one of its affiliated companies, is eligible to receive upfront, clinical, regulatory, and commercial milestone payments, plus royalties on net sales of resulting products. Lonza is responsible for manufacturing components that are related to its proprietary technologies, and Engitix will work on the R&D, manufacturing, and commercialization of the ADCs.
Engitix has developed a proprietary human extracellular matrix (ECM) platform that allows the study of disease biology directly in human tissue, according to a company official, who adds that this approach focuses on targets within the ECM itself, offering a differentiated pathway compared to traditional methods that focus on cell surface targets.
The collaboration enables Engitix to leverage Lonza’s established ADC technology platform to develop differentiated therapeutic candidates designed to selectively deliver potent payloads to tumor-selective targets identified through Engitix’s proprietary human ECM discovery platform, explains Giuseppe Mazza, MD, PhD, CEO and co-founder of Engitix.
‘We are committed to translating our unique understanding of the disease microenvironment into transformative therapies for patients with high unmet medical need,” he continues. “Licensing Lonza’s clinically validated conjugation and linker-payload technologies provides us with a powerful toolkit to develop next-generation ECM-targeted therapeutics with the potential for enhanced efficacy, reduced toxicity and improved therapeutic index.”
“We are pleased to collaborate with Engitix on this innovative program,” says Jan Vertommen, vice president of commercial development, advanced synthesis, Lonza. “By combining our ADC development and manufacturing expertise with Engitix’s unique ECM-based discovery platform, we aim to advance next-generation ADCs and unlock new possibilities in targeted therapies for patients.”
The post Engitix Licenses Lonza’s Technology to Advance ADC Therapies appeared first on GEN – Genetic Engineering and Biotechnology News.
Job dissatisfaction and health care access uncertainty grows in the U.S., new study finds
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. I admit that I didn’t finish rereading “The Odyssey” before I saw the movie last weekend, but it’s never too late. For now, scroll down to read a related First Opinion essay and to sign up for office hours with Bob Herman, STAT’s own Homeric chronicler of the business of health care.
STAT+: ‘Cochlear implant for blindness’ debuts in Europe, could launch in U.S. in 2027
Europeans can now receive a device that can partially restore their vision loss. Americans may not have to wait long to get it, either.
Science Corporation announced Wednesday that European regulators had approved the commercial sale of the startup’s retinal implant that improves eyesight for patients with age-related macular degeneration in their central vision, enough to read books and road signs more clearly.
“We have a cochlear implant for vision now,” said Science founder and CEO Max Hodak.

